维吾尔族女性乳腺癌与低分子量蛋白酶体蛋白表达缺失的关系

doi:10.3969/j.issn.1004-616x.2017.02.015

Abstract

Abstract:

OBJECTIVE: To compare the expression of low molecular-weight proteins (LMP) in breast cancers between Uighur and Han women. METHODS: We collected 165 cases of paraffin-embedded breast fibro adenoma or breast cancer tissues from Uighur and Han women and analyzed the protein expression of LMP2,LMP7 and LMP10 by immunohistochemistry. RESULTS: The total loss rate of LMP2 and LMP7 was significantly increased in breast cancer (67%/46.1%),the normal expression level was reduced with a significant difference (P < 0.01),the alternation trend of the loss rate of LMP10 was common to breast cancer and breast fibro adenoma (breast fibro adenoma 48%,breast cancer 56.5%),and the difference between the two groups is not statistically significant (P > 0.05). The alteration trend of the expression of LMP2,LMP7 and LMP10 was common to women from both Uighur and Han ethnic groups,in Uighur groups (43.1%,43.1%,47.7%),in Han groups (46%,42%,42%) and the difference between two ethnic groups is not statistically significant (P > 0.05). However,LMP2,LMP7 or LMP10 were significantly correlated with tumor lymph node invasion and distant metastasis (P < 0.05),LMP10 was significantly correlated with tumor size (P < 0.01). CONCLUSION: The loss of expression of LMP protein may be an important marker for breast cancer and was common to women from both Uighur and Han ethnic groups. This suggest that the loss may be a molecular mechanism for breast cancer and for both ethnic background.

Key words: low molecular-weight protein, breast cancer, Uighur women

CLC Number:

R737.9

GULZARIA·Aikula, MUKADDAS·Bahtiyar, HE Chunyu, AI Xiuqing, ZHANG Yujing, MUNIRE·Musa. Loss of expression of low molecular-weight proteins in breast cancers of Uighur women[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 146-150.

References

[1] BODAI BI,TUSO P. Breast cancer survivorship:a comprehensive review of long-term medical issues and lifestyle recommendations[J]. Perman J,2015,19(2):48-79.

[2] BLUM JS,WEARSCH PA,CRESSWELL P. Pathways of antigen processing[J]. Annu Rev Immunol,2013,31:443-473.

[3] MIZUKAMI Y,KONO K,MARUYAMA T,et al. Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma[J]. British J Cancer,2008,99(9):1462-467.

[4] MEHTA A M,JORDANOVA E S,KENTER G G,et al. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma [J]. Cancer Immun Immunother,2008,57(2):197-206.

[5] SO T,TAKENOYAMA M,MIZUKAMI M,et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer[J]. Cancer Res,2005,65(13):5945-5952.

[6] BANDOH N,OGINO T,KATAYAMA A,et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis[J]. Oncol Rep,2010,23(4):933-939.

[7] AYSHAMGUL H,MA H,ILYAR S,et al. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer[J]. Chin Med J,2011,124(3):341-346.

[8] TANAKA K. The proteasome:overview of structure and functions[J]. Proceed Jpn Acad,2009,85(1):12-36.

[9] TOWNSEND A R,ROTHBARD J,GOTCH F M,et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides[J]. J Immunol,1986,44(6):959-968.

[10] LUESCHER I F. A nonapeptide encoded by human gene MAGE-1 is recognized on HLAA1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E by catia traversari,Pierre van der Bruggen[J]. J Exp Med,1992,176(5):1453-1457.

[11] OHTA Y,FLAJNIK M F. Coevolution of MHC genes (LMP/TAP/class Ia,NKT-class Ib,NKp30-B7H6):lessons from cold-blooded vertebrates[J]. Immunol Rev,2015,267(1):6-15.

[12] ZHENG Y,PARSONAGE G,ZHUANG X,et al. Human leukocyte antigen (HLA) A*1101-restricted Epstein-Barr virus-specific T-cell receptor gene transfer to target nasopharyngeal carcinoma[J]. Cancer Immunol Res,2015,3(10):1138-1147.

[13] KHAN A N H,GREGORIE C J,TOMASI T B. Histone deacetylase inhibitors induce TAP,LMP,Tapasin genes and MHC class I antigen presentation by melanoma cells[J]. Cancer Immuno Immunother,2008,57(5):647-654.

[14] WEHENKEL M,BAN J O,HO Y K. Selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice[J]. Br J Cancer,2012,107(1):53-62.

[15] QIAO L,CHUN YAN H,PENG S,et al. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas:Association with disease progression[J]. Gastroenterology,2009,44:960-969.

[16] FAVOLE A,CASCIO P,CERRUTI F,et al. MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma[J]. Transl Oncol,2012,5(1):48-55.

[17] 成芳,张茜,刘卫华,等. 新疆2019例汉族、维吾尔族乳腺癌临床病理资料分析[J]. 肿瘤防治研究,2010,37(11):1312-1314.

[18] 木妮热·木沙江,籍素芝,古丽扎热叶·艾库拉. 新疆地区乳腺癌危险因素调查研究[J]. 临床肿瘤学杂志,2016,21 (1):34-40.

[19] 籍素芝,古丽扎热叶·艾库拉,朱相露,等. 新疆维吾尔族和汉族乳腺癌与HLA-DRB1基因多态性的分析[J]. 中华肿瘤防治杂志,2015,22(23):1791-1796.

[20] 木妮热·木沙江,古丽扎热叶·艾库拉,贺春钰,等. 新疆维吾尔族女性乳腺癌与HLA-DRB1基因多态性的关系及临床意义[J]. 癌变·畸变·突变,2015,27(5):366-369.

[21] GOBBI G,MIRANDOLA P,MICHELONI C. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions[J]. Int J Oncol,2004,25(6):1625-1629.

[22] BENDER C M,ZINGG J M,JONES P A,et al. DNA methylation as a target for drug design[J]. Pharm Res,1998,15(2):175-187.

[23] AYXAMGUL H,GULZARYA A,ABULIZI A,et al. Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women[J]. PLoS One,2012,7(9):44952.

[24] 古丽扎热叶·艾库拉,阿仙姑·哈斯木,阿布力孜·阿布杜拉,等. 维吾尔族妇女宫颈病变及人乳头状瘤病毒感染与抗原处理相关转运体TAP1和TAP2基因启动子甲基化的关系[J]. 中华病理学杂志,2012,47(7):438-442.

[25] 阿仙姑·哈斯木,哈提拉·吐尔逊,阿布力孜·阿布杜拉,等. 维吾尔族妇女宫颈病变组织中HPV感染与低相对分子质量蛋白酶体2和7基因启动子甲基化的关系[J]. 中华微生物学和免疫学杂志,2012,32(3):205-211.

[26] 阿仙姑·哈斯木. 维吾尔族宫颈癌发生与抗原呈递元件基因表达调控的关系研究[D]. 乌鲁木齐:新疆医科大学,2012.

[27] ASHLEY G R,WENDELL D J, RISHER J D,et al. DNA methylation-dependent epigenetic regulation of gene expression in MCF7 breast cancer cells[J]. Epigenetics,2006,1(1):32-44.

Loss of expression of low molecular-weight proteins in breast cancers of Uighur women

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[3]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[6]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[7]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[8]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[9]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[10]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[11]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[12]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.
[13]	XIAO Hongmei, PAN Tianqi, DONG Shunan, FU Lingmeng, WANG Shaokang, SUN Guiju. Menopausal status on risk for breast cancer from tea consumption: a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 395-399.
[14]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.
[15]	YANG Shaoyi, ZHANG Qingying, WU Jundong, LIN Qiuqiang, WANG Ruifeng, ZHENG Qingyuan, CAI Fen. Genetic variations in the mitotic checkpoint gene MAD1L1, and risk for breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 209-213.